| Literature DB >> 32424317 |
Zhiqiang Zhang1, Boris C Bernhardt2, Yifei Weng3,4, Sara Larivière4, Lorenzo Caciagli5,6, Reinder Vos de Wael4, Raúl Rodríguez-Cruces4, Jessica Royer4, Qiang Xu3, Neda Bernasconi4, Andrea Bernasconi4, B T Thomas Yeo7, Guangming Lu3.
Abstract
Thalamo-cortical pathology plays key roles in both generalized and focal epilepsies, but there is little work directly comparing these syndromes at the level of whole-brain mechanisms. Using multimodal imaging, connectomics, and computational simulations, we examined thalamo-cortical and cortico-cortical signatures and underlying microcircuits in 96 genetic generalized (GE) and 107 temporal lobe epilepsy (TLE) patients, along with 65 healthy controls. Structural and functional network profiling highlighted extensive atrophy, microstructural disruptions and decreased thalamo-cortical connectivity in TLE, while GE showed only subtle structural anomalies paralleled by enhanced thalamo-cortical connectivity. Connectome-informed biophysical simulations indicated modest increases in subcortical drive contributing to cortical dynamics in GE, while TLE presented with reduced subcortical drive and imbalanced excitation-inhibition within limbic and somatomotor microcircuits. Multiple sensitivity analyses supported robustness. Our multiscale analyses differentiate human focal and generalized epilepsy at the systems-level, showing paradoxically more severe microcircuit and macroscale imbalances in the former.Entities:
Year: 2020 PMID: 32424317 PMCID: PMC7234993 DOI: 10.1038/s42003-020-0958-5
Source DB: PubMed Journal: Commun Biol ISSN: 2399-3642
Fig. 1Morphological patterns were studied using a combined cortical thickness, thalamic volumetry, and thalamic surface-shape analysis (left).
a Cortical morphological differences between 107 patients with TLE and 96 idiopathic/genetic GE. Surface-based findings were corrected for multiple comparisons at a family-wise error level of 0.05. b Thalamic morphological differences. Boxplots lines/edge denote mean/range. For comparisons against controls, see Supplementary Fig. 1a. S/A/P superior/anterior/posterior, C/I contralateral/ipsilateral.
Fig. 2Superficial white matter and thalamic diffusion MRI profiling (left).
a, b Uni- and multivariate superficial white matter differences between 107 patients with TLE and 96 with GE. Surface-based findings were corrected for multiple comparisons at a family-wise level of 0.05. c Uni- and multivariate findings in the thalamus. Line and edge of boxplots denote the mean and range of the value. The error bar represents standard deviation. For comparisons of each cohort relative to controls, see Supplementary Fig. 1b.
Fig. 3Functional and microcircuit divergences based on biophysical modeling and functional connectivity analysis (left).
Schema of the connectome-informed biophysical simulation, showing a similar distribution of model parameters in our 65 HCs compared to a previous study[22], and thalamo-cortical functional connectivity analysis (right). a Results from connectome-informed biophysical models, showing decreased subcortical drive but increased recurrent excitation–inhibition on cortico-cortical dynamics in 107 patients with TLE relative to 96 patients with GE. Black outlines indicate the boundaries of well-established intrinsic functional networks[86]. b Differences in thalamo-cortical functional connectivity between TLE and GE. Findings were corrected for multiple comparisons at a family-wise error level of 0.05. For comparisons of TLE and GE relative to HCs, see Supplementary Fig. 1c.
Demographic data and clinical information. Age, onset, duration, and seizure frequency are presented in mean ± SD (range).
| GE-GTCS | TLE-HS | HC | |
|---|---|---|---|
| ( | ( | ( | |
| Sex (M/F) | 65/31 | 60/47 | 40/25 |
| Age (years) | 25.65 ± 7.85 | 27.29 ± 7.81 | 24.98 ± 4.96 |
| (16–50) | (16–48) | (21–40) | |
| Onset (years) | 19.72 ± 8.86 | 16.28 ± 9.15 | — |
| (7–49) | (0.25–43) | ||
| Duration (years) | 5.93 ± 6.36 | 10.87 ± 8.76 | — |
| (0.01–43) | (0.08–32) | ||
| Seizure frequency | 2.82 ± 9.86 | 9.69 ± 22.69 | — |
| (per month) | (0.01–62) | (0.03–150) | |
| Drug resistant (%) | 13 (13.5%) | 40 (37.4%) | — |
L LTLE-HS, R RTLE-HS, M male, F female.